Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Iradimed (IRMD) stock in plain English

Free brief · no signupStart here
IRMDPublished Nov 14, 2026
Iradimed Corp
Healthcare · Medical Devices
Manufactures non-magnetic intravenous infusion pumps and patient vital signs monitors.
Assets:
Winter Springs facilityoperates a 46,000 square foot manufacturing plant in Florida
MRidium pump linespecialized non-magnetic IV infusion systems for scanner rooms
3880 monitor platformwireless multi-parameter vital signs monitors engineered for MRI
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

80
OPS ScoreOperating finances
Latest quote
-1.28%$81.26
$1.04B
43.6×
$89.35M

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 14, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was IRMD. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Iradimed (IRMD) do?

Iradimed Corp (IRMD) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Manufactures non-magnetic intravenous infusion pumps and patient vital signs monitors. Builds non-magnetic infusion pumps and patient monitors designed specifically to operate safely inside MRI scanner. It is worth $1.04B on the market and sold $89.35M over the last year.

Market cap
$1.04B
P/E ratio
43.6×
Annual sales
$89.35M
Sector
Healthcare
Industry
Medical Devices
Brief updated
Nov 14, 2026

Brands and businesses behind IRMD

  • MRidium: This non-magnetic intravenous infusion system provides continuous drug delivery in MRI suites and earns through hardware and disposable tubing sales.
  • 3880 Monitor: This portable monitor measures patient vital signs near MRI machines and earns through device sales and single-use monitoring supplies.

IRMD’s flags, in plain English

Each flag is a number from Iradimed’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 14, 2026.

Stupid Cash

Can pay this year's bills 9 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.

Low debt

Low debt, only 0% of shareholder equity. The company owes very little compared with what it earns, so a bad year is less likely to force its hand.

Wide Gross Margin

Gross margin of 75.5% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Priced for Perfection

Priced at 43.6 times its yearly profit, so a lot of growth is already expected. The share price already assumes strong results, so news that is merely good can still send it down.

2 more green flags and 1 more risk note open with the free trial. Try it free for 7 days.

Questions about IRMD

How big is Iradimed?

Iradimed’s market cap is $1.04B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $89.35M: what customers paid the company over the last year, before any costs.

What is IRMD’s P/E ratio?

IRMD’s P/E ratio is 43.6×. Investors pay about 43.6 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with IRMD?

The company relies heavily on clearance from federal health regulators, where past warnings have delayed device submissions. That is one risk on Iradimed’s card. Its first risk flag is Priced for Perfection, explained above. The card holds 1 more risk note for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Iradimed’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. IRMD’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card